As one of the innovative antibody drug R&D enterprises with the richest and most diversified pipelines in China, we have developed over 50 innovative drug candidates with complete proprietary intellectual property rights, including 15+ innovative, world-leading bispecific antibody,multi-specific antibody and BsAb ADC drugs. 26 candidates have entered clinical trials in China, the US, Australia, New Zealand, etc..
Akeso pipeline landscape
Diversified and robust pipeline
